7h
Vietnam Investment Review on MSNLion TCR's Liocyx-M004 Receives FDA Clearance to Launch Global Multicenter Phase 2 Clinical Trial in HBV-Related Hepatocellular CarcinomaLion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from ...
Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.
3h
New Vision on MSNKampala dwellers at high risk of lung cancer, experts warnKAMPALA - People living in Kampala are at a high risk of developing lung cancer due to severe air pollution, health experts have warned. ;The experts said the air quality in Kampala is worse compared ...
Operator Good afternoon, everyone, and welcome to Gilead's fourth quarter and full year 2024 earnings conference call. My ...
It's important to prioritise your health at every stage of your life but over 50s have a few extra things they should keep an ...
Discover a potential breakthrough in treating severe liver scarring with a safe and effective therapy, as revealed by a recent Cleveland Clinic-led study.
Two new measures tied to outcomes drawn from data in the CLEAR phase 3 trial will be presented during the ASCO Genitourinary ...
Bayer is committed to advancing treatment in prostate cancer care, showcasing new analyses from its comprehensive clinical trial program for NUBEQA ® (darolutamide), which includes the ARANOTE, ...
8h
News Medical on MSNMachine learning tool predicts cancer treatment response based on genetic mutationsA groundbreaking study led by USC Assistant Professor of Computer Science Ruishan Liu has uncovered how specific genetic mutations influence cancer treatment outcomes-insights that could help doctors ...
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and fiscal year of 2024, provided an update on progress toward achieving key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results